AMRX
Amneal Pharmaceuticals, Inc.
AMRX's fundamentals are strong: earnings per share grew more than tenfold and its operating margin rose 3 points to 15%, though free cash flow fell 67%. At 53x earnings, it's trading in line with its usual 58x. Analysts expect that strong growth to continue.
AMRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Unavailable |
AMRX's revenue and profitability are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
AMRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $5.39 | -75% |
| Forward | 19x | $21.70 | — |
| Current | 53x | $21.70 | — |
| Fair | 58x | $23.71 | +9.2% |
| Expensive | 616x | $253 | +1064% |
Historical ranges are pointers, not guarantees.
AMRX's PE is in its fair range at 53x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
AMRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AMRX, with profitability improving.
AMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.14 | +178% |
| Q3 2026 | $0.41 | +1950% |
| Q2 2026 | $0.48 | +4700% |
| Q1 2026 | $0.37 | +$0.41 |
| Q4 2025 | $0.22 | +$0.60 |
| Q3 2025 | $0.02 | +$0.87 |
| Q2 2025 | $0.01 | +$0.80 |
| Q1 2025 | -$0.04 | +$0.69 |
| Q4 2024 | -$0.38 | +$0.10 |
AMRX's earnings per share have fallen from their peak: $0.41 over the past year, against $0.61 in late 2020.
AMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $862.7M | +10% |
| Q2 2026 | $796.2M | +9.9% |
| Q1 2026 | $722.5M | +3.9% |
| Q4 2025 | $814.3M | +11% |
| Q3 2025 | $784.5M | +12% |
| Q2 2025 | $724.5M | +3.2% |
| Q1 2025 | $695.4M | +5.5% |
| Q4 2024 | $730.5M | +18% |
AMRX's revenue has grown year over year for 22 quarters in a row: $863M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +2.1 points |
| Q2 2026 | 16% | +0.9 points |
| Q1 2026 | 20% | +5.2 points |
| Q4 2025 | 14% | +3.4 points |
| Q3 2025 | 9% | -3.7 points |
| Q2 2025 | 15% | +1.8 points |
| Q1 2025 | 14% | +16 points |
| Q4 2024 | 10% | +8.1 points |
AMRX's operating margin was 11% last quarter, up 2.1 points from the same quarter a year ago.
AMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $66.5M | -37% |
| Q2 2026 | -$51.9M | -185% |
| Q1 2026 | -$34.9M | -$29.2M |
| Q4 2025 | $108.5M | +5.5% |
| Q3 2025 | $106.2M | -15% |
| Q2 2025 | $61M | +110% |
| Q1 2025 | -$5.8M | +$7.9M |
| Q4 2024 | $102.9M | -18% |
AMRX still generates free cash flow, though less than at its 2020 peak: $88M over the past year.
AMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +7.6M shares |
| 1 year | +3.4% | +11M shares |
| 3 years | +117% | +181M shares |
| 5 years | +121% | +184M shares |
| Available history | +154% | +204M shares |
AMRX has 336M diluted shares, up 3.4% from a year ago.
AMRX Net Leverage
AMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 86.7 | Overbought |
AMRX's weekly RSI is 69 (neutral) and its Stochastic is 87 (overbought).
AMRX PE vs Healthcare Sector
| Metric | AMRX | Sector median | Relative |
|---|---|---|---|
| PE | 53x | 26x | 105% above |
| PE % | 40 | 29 | 11 pts above |
AMRX is trading at 53x earnings, a 105% premium to the Healthcare sector's median of 26x.
AMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 6.6% above |
| 20 week MA | $18.8 | 15% above |
| 50 week MA | $15.5 | 40% above |
| 100 week MA | $12.1 | 79% above |
| 200 week MA | $8.62 | 152% above |
AMRX is in an uptrend: it's above all five of its weekly moving averages, and 152% above its 200-week average.
AMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.51 | $4.43 | -1.8% |
| 2021 | $4.43 | $5.07 | +14% |
| 2022 | $5.07 | $2.20 | -57% |
| 2023 | $2.20 | $6.07 | +176% |
| 2024 | $6.07 | $7.82 | +29% |
| 2025 | $7.82 | $13.0 | +66% |
| 2026 YTD | $13.0 | $21.7 | +68% |
AMRX's yearly returns have swung widely, from +176% in 2023 to −57% in 2022. It's up 68% so far in 2026.